Company intelligence / Profile preview

Rejoni

Bedford, Massachusetts, United Statesrejoni.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Rejoni has completed enrollment in a pivotal clinical trial for its Juveena Hydrogel System, designed to prevent intrauterine adhesions following uterine surgery. The company plans to submit results to the FDA. No FDA-approved treatment currently exists for this indication. Early clinical data and physician commentary suggest the device could address a significant unmet need in women's reproductive health by reducing complications from IUAs. No commercial products yet; still investigational.

Therapeutic areas: Women's Health
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Juveena Hydrogel System

Phase 2

Indications: Intrauterine adhesions prevention

Partnerships

Not specifically disclosed; works with leading physicians and academic centers for trials.

Beyond the preview

Go deeper on Rejoni.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rejoni.

Explore the full profile